What diseases does Qlosi eye drops treat

Qlosi eye drops are a cholinergic muscarinic agonist topical ophthalmic preparation. The main active ingredient is pilocarpine hydrochloride.

What diseases does Qlosi eye drops treat?

It is suitable for the treatment of presbyopia in adults.

Qlosi eye drops usage and dosage

1. Routine administration

Instill one drop of QLOS eye drops in each eye, and repeat the second drop after 2 to 3 hours to achieve a therapeutic effect of up to 8 hours. Qlosi Eye Drops can be used daily or as needed up to twice daily.

2. Concomitant medication

If more than one topical ophthalmic drug is used at the same time, the various drugs must be administered at least 5 minutes apart.

3. Single-dose vial use

Please discard single-patient vials after single use.

Qlosi Eye Drops Dosage Forms and Specifications

Qlosi Eye Drops are a clear, colorless to yellowish ophthalmic solution in single-patient vials containing 0.4% (4 mg/mL) pilocarpine hydrochloride.

The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Contraindications of Qlosi Eye Drops

Qlosi Eye Drops are contraindicated in patients with known hypersensitivity to the active ingredient or any excipients.

Qlosi Eye Drops Precautions

1. Blurred Vision

Miotics, including Qlosi Eye Drops, may cause accommodation spasm. Patients are advised not to drive or operate machinery when their vision is unclear (e.g., blurred vision).

In addition, patients may experience temporary dimming or darkening of vision when using miotic agents, including Qlosi eye drops. Patients are advised to exercise caution when driving at night and performing other hazardous activities under poor lighting conditions.

2. Risk of retinal detachment

There have been rare case reports of retinal detachment when miotic agents were used in susceptible individuals and patients with existing retinal diseases. It is recommended that all patients have their retinas examined before starting treatment. Patients are advised to seek immediate medical attention if they suddenly experience flashes of light, floaters, or vision loss.

3. Iritis

When iritis is present, the use of Qlosi eye drops is not recommended because synechiae may form between the iris and lens (posterior iris synechiae).

4. Wearing contact lenses

Patients who wear contact lenses should be informed to remove the lenses before instilling Qlosi eye drops and to wait 10 minutes after administration before putting the lenses back on.

5. Potential risk of eye damage or contamination

To prevent eye damage or contamination, avoid allowing the tip of a single-patient vial to come into contact with the eyes or any other surface.

Adverse reactions of Qlosi eye drops

The most commonly reported treatment-related adverse events are pain at the administration site and headache. Pain at the administration site manifests as a brief stinging sensation in the eyes during instillation. The ocular adverse reaction reported in 2%-5% of patients is blurred vision.

Most adverse events were mild, transient, and self-resolving. If the patient experiences any unmentioned abnormal reaction, he or she should inform the doctor in time and it is recommended to use the medicine correctly under the guidance of the doctor.